Abstract: While it may seem at first that antihypertensive drug combinations run counter to the desire to 'personalize' the management of hypertension, the best combinations have predictable efficacy in different individuals and subpopulations. Race is probably not a valid surrogate for clinically meaningful genetic variation or guide to therapy. Most guidelines suggest similar blood pressure goals for different races but drug treatment recommendations have diverged. In the United States, race is not considered to be a major factor in drug choice, but in England and other countries, initial therapy with reninangiotensin system blocking drugs is not recommended in Blacks. In this review we: (1) examine new trends in race-based research; (2) emphasize the weaknesses of race-based treatment recommendations; and (3) explore the effects of a new combination, renin inhibition (aliskiren) and amlodipine, in African Americans.
Introduction
As implied in the ongoing work of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC), the general principles of hypertension management apply to both genders and to all ages, races and ethnic groups [Chobanian et al. 2003a] . At the same time there are subtle differences in basic pathophysiology, morbidity/mortality rates, and treatment responses among various races, including African Americans. In contrast, current British Hypertension Society recommendations have attempted to incorporate racial differences into guidelines and have suggested that initial monotherapy with diuretics or calcium channel blockers should be given to Blacks or individuals over age 55, while reninangiotensin system (RAS) blocking drugs should given to non-Blacks and individuals under the age of 55 [Williams et al. 2004 ; http://guidance.nice.org.uk/CG/Wave2/14/ Development]. The International Society for Hypertension in Blacks (ISHIB) has a somewhat different approach [Flack et al. 2010; Douglas et al. 2003 ] based on expert consensus that suggests different blood pressure (BP) targets. This review compares basic science and clinical data on race and antihypertensive drugs with current guidelines for African Americans with hypertension. In addition to efficacy data, the role of antihypertensive drugs in organ protection is also discussed. Particular attention is directed to a new drug combination: renin inhibitor (aliskiren) and L-type calcium channel blocker (amlodipine).
Limitations of race as a scientific and clinical construct
The scientific approach to race and ethnicity has changed in recent years. Widespread recognition of disparities in health outcomes has partially diffused some of the emotional barriers to racial identification and the goal of reducing health disparities has served as a socially and scientifically acceptable rationale for race-based studies. A full discussion of the effect of race on hypertensionattributable morbidity and mortality is far beyond the scope of this manuscript but it is clear that the impact of race on disease is diffused and confounded by environmental, socioeconomic, sociocultural, statistical, and practical factors that must be considered. Overall, race is not very useful as a genetic marker and offers relatively little as a guide to therapy.
Geneenvironmentaging interactions
Hypertension and many other clinical disorders are now viewed as the product of genetic predisposition and environmental exposure. Essential hypertension is a polygenetic trait with a relatively low identifiable genetic contribution; estimates of heritability are generally well below 50%, even in selected populations [DeStefano et al. 2004; Fava et al. 2004; Wilk et al. 2004; Snieder et al. 2000] . In contrast, acquired characteristics (especially obesity) are usually important as is the aging process, another important factor that interacts with the geneenvironment continuum, further modifying and confounding phenotypic presentations [Mitchell et al. 2008; Wilk et al. 2004] and clinical care.
A recent manifestation of interest in genomic research is the emerging field of pharmacogenetics, which is based on the idea that a specific genetic polymorphism representing a specific biologic mechanism can cause an important variation in the pattern of drug response or drug metabolism in different individuals or populations. While it is true that certain genetic variations such as the homozygous G12269A alleles or homozygous angiotensin-converting enzyme (ACE) haplotypes (I/I or D/D) have been reported to predict the magnitude of the early response to ACE inhibition [Bhatnagar et al. 2007] , the clinical meaning of this finding is unclear.
Complex phenomena such as drug responses often depend at least as heavily on environmental influences as on genetic traits. For instance, the BP response to a renin inhibitor is usually somewhat attenuated in individuals with low plasma renin activity (PRA; a genetic trait common in African Americans) [Sealey and Laragh, 2009] , but low PRA can be induced in individuals of any race by increasing dietary salt intake but the pressor sensitivity to angiotensin II is dependent on complex interactions involving time, genetic and dietary factors, physiologic responses, and cellular processes African Americans tend to inherit the trait of salt-sensitivity, which, as the term suggests, identifies one third to one half of all hypertensive individuals whose BPs rise excessively in response to sodium chloride loading [Price et al. 2002; Morris et al. 1999; Svetkey et al. 1996; Weinberger, 1996; Luft et al. 1991] .
This interplay between genes and environment also appears to affect cardiovascular outcomes, stroke, and end-stage renal disease (ESRD) in African Americans and in Whites. In the past, race (as a putative genetic surrogate) was considered to be a principal cause of outcome disparities but more recent studies demonstrate that higher cardiovascular morbidity in blacks may be more attributable to poor health habits ('acquired' characteristics), including higher prevalence of obesity, diabetes, unhealthy diet (high-salt, high-fat, high-calorie content), cigarette smoking, and sedentary lifestyle [Karlamangla et al. 2010] . Reduced care access in many areas also plays an obvious role in increased morbidity.
Labeling inaccuracy and racial mixing Another barrier to racial research is the relative inaccuracy of the racial categories most commonly employed, whether based on observer identification or self-identification. Since 1997, major racial categories defined by the Office of Management and Budget (OMB) are American Indian/Alaska Native, Asian, Black/African American, Hispanic/Latino, and Native Hawaiian/Pacific Islander. In 2003, the OMB revised the standards to sub-stratify each category by multiple permutations too numerous to include in this paper (see http://www.naphsis. org/NAPHSIS/files/ccLibraryFiles/Filename/00 0000001003/Race%20and%20Ethnicity.pdf). The presence of individuals of mixed racial heritage further erodes labeling accuracy, particularly since most self-definition questionnaires instruct the individual to indicate a single race. Race and ethnicity are often considered to represent two different dimensions of a population, but this distinction has obvious limitations. Clearly, as the number of individuals of mixed racial heritage continues to increase, the value of race as a genetic surrogate will decline further.
Population variation and drug responses
More subtle but even more problematic for those interested in race-based practice guidelines is the substantial interindividual variation in genetic polymorphisms and phenotypic traits that occur within racial subpopulations. The frequency distribution for PRA in White and Black populations is similar [Chrysant et al. 1979] as is the distribution of responses to ACE inhibition [Mokwe et al. 2004; Sehgal, 2004; Chrysant et al. 1979] , although Blacks have somewhat lower mean BP responses to monotherapy with beta-blockers [Buhler, 1988] , ACE inhibitors [Buhler, 1988] , and renin inhibitors [Sealey and Laragh, 2009] . It should be quickly noted that in each case, there is sufficient interindividual BP response heterogeneity to raise the question of how any race-based guideline for RAS blockade can be applied rationally. This concern was a major factor in the omission of race-based recommendations from the JNC 7 hypertension treatment guideline [Chobanian et al. 2003b] and more recently in the New York State Medicaid guideline for treatment of hypertension in diverse populations [Wrobel et al. 2011] . In general, the current approach taken in the US is one of race neutrality. From a practical perspective, the most effective approach may be to simply administer a RAS blocker (alone or in combination with a thiazide or amlodipine as warranted by the level of BP and the individual's profile), observe the strength of the clinical effect over the next several weeks (regardless of race), and then to add additional medications if needed.
Medication adherence
Although low BP goal attainment rates and poor outcomes have been reported among African Americans, such differences are not necessarily biological in nature, provided that appropriate therapy is used, nor should they be generalized without in-depth knowledge of the study. RAS blockeramlodipine combination therapy is equally efficacious in Black and non-Black patients [Jamerson et al. 2008] and ALLHAT demonstrated that CVD outcomes were similar between blacks and whites [Wright et al. 2005] . Still, medication adherence rates have been reported to be low in Blacks, who often do not refill their prescriptions as recommended due in part to a variety of reasons including access to healthcare, insurance, and other socioeconomic factors [Vulic et al. 2010] . In an analysis of hypertension care in South Carolina, adherence was better in those prescribed single-pill combinations compared to those receiving the individual components (59% vs. 48%; p < 0.05). Even though African Americans and Whites were equally likely to receive the single-pill combinations, adherence to combination therapy was lower among African American (55% vs. 61%, respectively; p < 0.05) [Dickson and Plauschinat, 2008] .
Several cultural factors influencing adherence have been noted, including a higher general level of distrust among African American patients and paucity of diversity among healthcare leaders who then fail to design appropriate resources to accommodate underserved populations. In studies that have tried to control for attitudes and other comorbidities (smoking, weight, etc.), interracial differences in BP control are minimal or absent, suggesting that generalization across ethnicity is not fully warranted [Kressin et al. 2010] . Intermittent contact with a healthcare provider is often inadequate to maintain and reinforce complicated lifestyle modifications and recommended treatment. Race-related clinical inertia among practitioners is also a factor that affects the way BP goals have been measured. For example, one study showed that counseling in diet and exercise is performed less often in African Americans than in whites, Asians, or Hispanics, and that suboptimal doses are often given to these patients who then do not meet recommended BP targets [Bonds et al. 2004] . It is believed that more effective lifestyle counseling would substantially improve BP control in Blacks.
Need for combination therapy Increasing use of initial combination antihypertensive therapy renders the question moot as to which is the best first-line agent. Based on numerous subgroup analyses, there is no convincing evidence of any racial difference in BP response to combination therapy with either RAS blockerdiuretic or RAS blockeramlodipine. Furthermore, the practical need for combination therapy also argues against racebased therapeutic guidelines because: (1) combination therapy is required in most individuals with hypertension to achieve and maintain adequate long-term BP control; (2) preferred combinations have similar pharmacokinetic properties but diverse mechanisms of action; and (3) the best combinations are built around agents that have beneficial outcomes in virtually all demographic subpopulations. In each case, the best available combinations are those that contain a RAS blocker and either a dihydropyridine calcium channel blocker or a thiazide-type diuretic [Gradman et al. 2010; Mancia et al. 2007; Chobanian et al. 2003a] .
Other practical issues Overall, the likelihood of major improvement in hypertension therapy based on genetic profiling is very small based on our current knowledge and healthcare budget. Even if useful genetic testing becomes widely available, it is impractical to assume that such information could be applied consistently and competently in today's clinical practice world. Current training of general health professionals in such applications is wholly inadequate and there is no inexpensive or practical way to remedy this knowledge deficit. In such a climate, any tendency for undereducated practitioners to misinterpret or misapply a simplistic paradigm could easily lead to withholding of a potentially beneficial drug. Instead, simply observing the therapeutic effect of a drug (or combination) in each individual provides a rational basis for chronic therapy that is far more reliable, cost effective, and directly relevant to the individual being treated.
Hypertension pathophysiology in African Americans
Various scientific observations have been made about the pathogenesis and impact of hypertension in African Americans. With the exception of differences in the interaction of RAS activity and dietary salt intake, none of these subtleties exert a major impact on clinical practice.
Hypertension mechanisms
Virtually all individuals with early or mild hypertension appear to have inappropriately high cardiac output and inappropriately high systemic vascular resistance, most often associated with weight gain and obesity [Messerli et al. 1982] . BP elevations later in life reflect further increases in systemic vascular resistance [Messerli et al. 1983] along with increased arterial stiffness Messerli et al. 1979] , although one study suggests a steeper relationship between arterial stiffness and systolic BP in older Blacks with hypertension [Ferreira et al. 1999] . The increased sympathetic nervous activity that characterizes chronic hypertension in general also appears to be common to all races [Pratt et al. 1992] , although longer recovery time to stress provocation has been reported in African Americans [Nelesen et al. 1995] . PRA tends to be low in African Americans, as already discussed.
Some studies have suggested that there may be membrane ion transport differences in blacks [Hatori et al. 1990 ] and variations in intracellular cation concentrations have also been reported [Wright et al. 2003 ]. Blacks have a lower rate of potassium clearance from plasma, suggesting reduced ATP-ase activity associated with insulin resistance [Suh et al. 2004] , and it has been suggested that cellular potassium deficiency explains the exaggerated vasoconstrictive responses to cold seen in African Americans [Sudhir et al. 1997] . In at least one study, plasma aldosterone was found to be higher in Blacks as compared with Whites [Kotchen et al. 2009 ].
Perhaps most importantly, there are differences in the interplay of the RAS and renal salt and water excretion in African Americans. African Americans tend to consume a diet higher in salt and lower in potassium content than their nonBlack counterparts and in addition, they also have a higher prevalence of salt sensitivity [Svetkey et al. 1996; Weinberger, 1996; Luft et al. 1991] . Salt sensitivity is not purely genetic because increased potassium intake in Blacks reduces salt sensitivity [Morris et al. 1999] . Blunted suppression of the RAS in response to a salt load has been reported in Blacks [Price et al. 2002] and a few experts believe that the low PRA in Blacks masks an underlying increase in renal and 'tissue' reninangiotensin activity. These ideas arise principally from short-term studies, however, and the applicability of these laboratory observations to clinical BP management is unclear.
Fortunately, sodium restriction is at least as effective in Blacks as Whites [Sacks et al. 2001] and, in general, dietary salt restriction increases the likelihood of BP control in any salt-sensitive individual [Weir et al. 1998 ]. When salt-sensitive individuals ingest a high-salt diet, however, dihydropyridine calcium channel blockers have been shown to be more effective than ACE inhibitors in maintaining a lower BP [Weir et al. 1998 ].
Organ damage
Newer analyses suggest that ischemic heart disease outcomes are more closely related to sociocultural factors than race [Karlamangla et al. 2010] . Differences in other cardiovascular risk factors also previously attributed to race are also being re-examined. For example, left ventricular mass tends to be higher in African Americans but when adjusted for body weight, age, gender and other factors, interracial differences in left ventricular hypertrophy are reduced [Skelton et al. 2003 ] and may not exist at all in women [Taylor et al. 2007] . Although the strength of association of higher risk scores and adverse outcomes is greater in minority populations [Hurley et al. 2010] , racial outcome disparities in heart failure also may be explained to a very large extent by socioeconomic factors and lower rates of medication adherence [Roberts et al. 2010; Wu et al. 2010] .
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Perhaps the most important racial difference in hypertension-attributable organ damage is in the impact of hypertension on the kidney. The Atherosclerosis Risk in Communities (ARIC) study found that the presence of a glomerular filtration rate (GFR) that was either too low or too high correlated with increased 17-year risk of more rapid progression to ESRD [Bash et al. 2010] . In African Americans, ESRD is much more commonly associated with hypertension or diabetes and occurs much earlier than in age-adjusted non-Blacks [Bash et al. 2010] , with low income as another major risk factor for disease progression [Norris et al. 2006] .
Race and therapeutic outcome benefits
In general, African Americans benefit from antihypertensive therapy (including RAS blockers) in a similar fashion as other racial groups. Thus, avoidance of RAS blockers as initial antihypertensive therapy in Blacks, as suggested by current European guidelines, is again not fully justifiable.
Cardiovascular disease
In general, there appears to be no major diminution of the cardiovascular benefits with antihypertensive drugs in African Americans compared with non-Blacks. African Americans in ALLHAT derived the same cardiovascular benefits as non-Blacks irrespective of which of the three major drug classes (thiazide, ACE inhibitor, or calcium channel blocker) were used as firstline therapy [Wright et al. 2005] . Even though ACE inhibitor monotherapy responses are attenuated in some Blacks, the benefits attributable to these drugs in clinical trials (all of which actually involve combination therapy) are similar as long as the BP is controlled to an equal degree [Izzo, 2010; Leenen, 2004] . Some racial deviations in benefits have been reported, however. In the LIFE study, atenolol was 66% better than losartan in reducing cardiovascular mortality in Blacks, but in Whites losartan was 18% better than atenolol [Julius et al. 2004] .
Chronic kidney disease
The Modification of Diet in Renal Disease (MDRD) study followed renal function deterioration over 3 years in group with renal damage treated with dietary modification and antihypertensive drugs [Hebert et al. 1997; Klahr et al. 1994] . The age-related rate of GFR decline was lower in Whites than Blacks but Blacks with lower BPs had slower deterioration in renal function [Hebert et al. 1997] . In both Blacks and Whites, higher baseline urine protein excretion was associated with a greater beneficial effect of low BP on the rate of GFR decline. These findings led guideline writers to recommend much lower goal BPs (<125/75 mmHg) in patients with proteinuria (>1 g/day). In the African American Study of Kidney Disease (AASK) in Blacks with hypertension and nephrosclerosis, ACE-inhibitor-based therapy was found to retard the progression to ESRD to a greater degree than therapy based on beta-blockade or calcium channel blockade [Agodoa et al. 2001] . In AASK, however, the initial design did not allow the combination of ACE inhibitor and amlodipine. In the long-term follow-up AASK, there was continued progression to ESRD in the majority of individuals despite good BP control (mean 133/78 mmHg) and continued use of ACE inhibitors (>80%) [Appel et al. 2008] . More recently, a retrospective analysis of the ACCOMPLISH trial demonstrated that combining amlodipine with and ACE inhibitor slows the age-related decrease in renal function to a greater degree than an ACE inhibitorthiazide combination .
RAS blockeramlodipine combinations
The importance of combination drug therapy in hypertension has already been emphasized. The American and British Societies of Hypertension both identify a 'preferred' strategy for two-drug combinations: RAS blocker (ACE inhibitor or angiotensin receptor blocker [ARB]) plus diuretic or RAS blocker plus calcium channel blocker [Gradman et al. 2010; Williams et al. 2004] . In the future, renin inhibitors may be included in this algorithm as an alternative to ACE inhibitors and ARBs if outcome data are positive [Lee and Oh, 2009; Parving et al. 2009; Riche et al. 2009; McMurray et al. 2008; Persson et al. 2008] .
Theoretical advantages
The advantages of combining a RAS blocker with amlodipine include a not only balanced effect on systemic hemodynamics but also complementary effects on signal transduction in excitable cells such as sympathetic neurons and most likely vascular smooth muscle cells [Zion and Izzo, 2011; Fernandez et al. 2005 Fernandez et al. , 2003 ]. The ability of RAS blockers to ameliorate amlodipine-induced sympathetic nervous activation and increased PRA is reasonably well understood. Less well known are the direct cellular effects of the combination of a RAS blocker and amlodipine that, in parallel: (1) reduce AT 1 receptor-mediated release of calcium from intracellular stores effects; and (2) limit the rate of entry of calcium into the cytoplasm via L-channels in the cell membrane [Fernandez et al. 2005 [Fernandez et al. , 2003 . With respect to cardiovascular and renal outcomes, several trials are ongoing; it seems most likely that BP effects and outcome benefits similar to ACE inhibitors and ARBs will be found [Persson et al. 2010; Delea et al. 2009; Lee and Oh, 2009; Littlejohn et al. 2009; Parving et al. 2009 ].
Aliskiren-amlodipine combination therapy
Blood pressure efficacy Long-term efficacy and tolerability of the aliskirenamlodipine combination in a general hypertension population has been clearly demonstrated [Littlejohn et al. 2009 ]. Short-term BP efficacy and tolerability of the aliskirenamlodipine combination in African Americans has also been demonstrated in a parallel-arm study of 147 investigator-identified individuals with stage 2 hypertension [Black et al. 2011] . After 8 weeks of therapy, the combination was superior to amlodipine monotherapy in lowering clinic seated systolic BP and 24-hour ambulatory systolic BP (by about 6 mmHg each, À32.5 vs. À26.7 and À19.8 vs. À14.0 mmHg, respectively, each p < 0.05). BP control rates (<140/ <90 mmHg) were better with the combination (57% vs. 48%, p ¼ 0.051), which also lowered central systolic BP, as estimated from radial arterial tonometry, by about 56 mmHg more than amlodipine alone (À29.8 vs. À24.2 mmHg, p < 0.05). The antihypertensive effects of the combination were preserved in those with obesity (body mass index [BMI] >32.5 kg/m 2 ) or metabolic syndrome [Weinberger et al. 2010] (Figure 1 ). Mean plasma renin activity of these individuals was about 1 ng/ml/h, with wide variation.
Tolerability
Overall, the tolerability of renin inhibitors is quite good, with little suggestion that there are racial differences in the occurrence of adverse events. By comparison, ACE inhibitors have an increased likelihood of causing a nonproductive cough or, more seriously, angioedema, in African Americans and other minorities [Morimoto et al. 2004; Gainer et al. 1996] , although it appears that the attribution of adverse events to ACE inhibitors is heavily influenced by payers' policies that restrict the use of ARBs to individuals reported by their physicians to be intolerant to ACE inhibitors [Cosentino et al. 2001] . With respect to the combination of aliskiren and amlodipine, the most common side effect is edema, but the rate of drug discontinuation is low, particularly when the lower dose of amlodipine (5 mg/day) is used.
Other factors
One of the most intriguing aspects of aliskiren is its long-lasting effect on BP. Although relatively poorly absorbed from the gastrointestinal tract, aliskiren is quite potent and its pharmacodynamic half-life markedly exceeds 24 hours [Palatini et al. 2010] . This might carry with it potential importance in individuals more likely to miss drug doses, a characteristic that is more frequent in minorities. Thus, the combination of aliskiren and amlodipine includes two drugs with very long durations of action, a possible protective effect in individuals not fully adherent to daily drug dosing recommendations [Palatini et al. 2010] .
Conclusion
The search for relevant genetic or acquired biomarkers to improve or 'personalize' therapy continues but race is a poor surrogate for genetic variation and does not qualify as a useful therapeutic guide in hypertension. Accordingly, the attractiveness and applicability of the British approach of race-based choice of antihypertensive agents is questionable. Major guidelines recommend that Blacks pay particular attention to reducing dietary salt and increasing dietary potassium content. It is also generally accepted that combination antihypertensive therapy is usually required for optimal BP control. The combination of a RAS blocker (ACE inhibitor, ARB, or perhaps renin inhibitor) with either amlodipine or a thiazide-type diuretic is particularly attractive to lower BP and reduce hypertensionattributable adverse outcomes. The combination of aliskiren and amlodipine has been tested in African Americans with good BP efficacy and tolerability.
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